EUVIMEDEUVIMED entdecken
Open Access

Systematic Analyses of the Resistance Potential of Drugs Targeting SARS-CoV-2 Main Protease

Julia M Flynn iD, Qiu Yu J Huang, Sarah N Zvornicanin, Gila Schneider-Nachum, Ala M Shaqra, Nese Kurt Yilmaz iD, Stephanie A Moquin, Dustin Dovala, Celia A Schiffer iD, Daniel N A Bolon

ACS Infectious Diseases · 14.07.2023 · 9 (7) · 1372-1386

DOI: 10.1021/acsinfecdis.3c00125 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ACS Infectious Diseases, online erschienen am 30.06.2023. Verfasst von Julia M Flynn und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry and Molecular Biotechnology, University of Massachusetts Chan Medical School, Worcester, Massachusetts 01605, United State…. Hauptthemen laut MEDLINE: COVID-19. Die Arbeit wurde bisher 38-mal zitiert (Crossref) und nennt 64 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS, NIGMS NIH HHS, Novartis.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Drugs that target the main protease (Mpro) of SARS-CoV-2 are effective therapeutics that have entered clinical use. Wide-scale use of these drugs will apply selection pressure for the evolution of resistance mutations. To understand resistance potential in Mpro, we performed comprehensive surveys of amino acid changes that can cause resistance to nirmatrelvir (Pfizer), and ensitrelvir (Xocova) in a yeast screen. We identified 142 resistance mutations for nirmatrelvir and 177 for ensitrelvir, many of which have not been previously reported. Ninety-nine mutations caused apparent resistance to both inhibitors, suggesting likelihood for the evolution of cross-resistance. The mutation with the strongest drug resistance score against nirmatrelvir in our study (E166V) was the most impactful resistance mutation recently reported in multiple viral passaging studies. Many mutations that exhibited inhibitor-specific resistance were consistent with the distinct interactions of each inhibitor in the substrate binding site. In addition, mutants with strong drug resistance scores tended to have reduced function. Our results indicate that strong pressure from nirmatrelvir or ensitrelvir will select for multiple distinct-resistant lineages that will include both primary resistance mutations that weaken interactions with drug while decreasing enzyme function and compensatory mutations that increase enzyme activity. The comprehensive identification of resistance mutations enables the design of inhibitors with reduced potential of developing resistance and aids in the surveillance of drug resistance in circulating viral populations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19HumansSARS-CoV-2LeucineLactamsNitrilesCoronavirus 3C ProteasesIndazolesTriazinesTriazoles

Stichwörter der Autor:innen

MproSARS-CoV-2deep mutational scanningproteaseresistancevirology

Substanzen

LeucineLactamsNitriles3C-like proteinase, SARS-CoV-2Coronavirus 3C ProteasesensitrelvirIndazolesTriazinesTriazoles

Autor:innen und Institutionen

  • Department of Biochemistry and Molecular Biotechnology, University of Massachusetts Chan Medical School, Worcester, Massachusetts 01605, United States.
  • Novartis Institute for Biomedical Research, Emeryville, California 94608, United States.

ORCID-Profile: Julia M Flynn, Nese Kurt Yilmaz, Celia A Schiffer

Förderung

  • NIAID NIH HHS
  • NIGMS NIH HHS
  • Novartis

Zitieren

APA

Flynn, J. M., Huang, Q. Y. J., Zvornicanin, S. N., Schneider-Nachum, G., Shaqra, A. M., Yilmaz, N. K., Moquin, S. A., Dovala, D., Schiffer, C. A., & Bolon, D. N. A. (2023). Systematic Analyses of the Resistance Potential of Drugs Targeting SARS-CoV-2 Main Protease. ACS Infectious Diseases, 9(7), 1372-1386. https://doi.org/10.1021/acsinfecdis.3c00125

Vancouver

Flynn JM, Huang QYJ, Zvornicanin SN, Schneider-Nachum G, Shaqra AM, Yilmaz NK, et al. Systematic Analyses of the Resistance Potential of Drugs Targeting SARS-CoV-2 Main Protease. ACS Infectious Diseases. 2023;9(7):1372-1386. doi:10.1021/acsinfecdis.3c00125

BibTeX
@article{Flynn2023,
  author = {Flynn, Julia M and Huang, Qiu Yu J and Zvornicanin, Sarah N and Schneider-Nachum, Gila and Shaqra, Ala M and Yilmaz, Nese Kurt and Moquin, Stephanie A and Dovala, Dustin and Schiffer, Celia A and Bolon, Daniel N A},
  title = {Systematic Analyses of the Resistance Potential of Drugs Targeting SARS-CoV-2 Main Protease},
  journal = {ACS Infectious Diseases},
  year = {2023},
  volume = {9},
  number = {7},
  pages = {1372--1386},
  doi = {10.1021/acsinfecdis.3c00125}
}
Kostenlos starten →